The study was carried out to examine the effect of selective α1 adrenoceptor agonist midodrine hydrochloride vs. β-adrenergic blockade metoprolol in the treatment of children with postural orthostatic tachycardia syndrome (POTS).
ostural orthostatic tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the absence of orthostatic hypotension, has been the focus of increasing clinical interest over the past 15 years. 1 In the USA, clinicians have estimated that this syndrome might affect at least 500,000 to 1 million Americans. 2 There is a decisive 4-6:1 female predilection, with a mean age of 29 years and an age range from 15 to 50 years. 1 At present, POTS is defined as the presence of orthostatic intolerance (OI) symptoms associated with a heart rate increase of 30 beats/min (or a rate that exceeds 120 beats/min) within the first 10 min of standing or upright tilt, which is seen in the absence of other chronic debilitating disorders, prolonged bed rest, or medications that impair vascular or autonomic tone. 3 It is very prevalent in children, and was one of the clinical manifestations of chronic OI. According to our previous results, POTS was also one of the main causes of unexplained syncope in children. Treatment of POTS most often involves pharmacotherapy, commonly with β-blockers; however, there are disputations on the effect of β-blockers for POTS. In 2002, Stewart et al 4 reported that esmolol could not improve orthostatic tolerance and hemodynamics in POTS. Midodrine hydrochloride, a selective α-agonist, is particularly attractive because it significantly decreases venous capacitance and might be effective at doses that do not increase blood pressure. Furthermore, midodrine does not cross the blood-brain barrier and thus has no central nervous system side effects. Up to now, only 2 studies in adults with POTS suggested that midodrine hydrochloride therapy might be an effective preventive measure. However, there are few studies about midodrine hydrochloride in the treatment of POTS in children. In 2009, midodrine hydrochloride was described as a first line medication in Japanese Clinical Guidelines for Child Orthostatic Dysregulation. 5 Here, we
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reported the results of a controlled trial conducted to investigate the efficacy of midodrine hydrochloride vs. metoprolol in the treatment of POTS in children. 1 Informed parental consent and the child's assent were obtained for each patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee, and it was approved by the Ethics Committee of Peking University First Hospital.
Methods

Patients
Study Design
A total of 53 patients were assigned into 3 groups. Group I comprised 19 patients given midodrine hydrochloride as first-line therapy along with conventional therapy, including increased intake of water and salt, avoidance of predisposing situations, maneuvers to prevent blood from pooling in the lower extremities (leg crossing) and to abort the episode (supine posture), and reassurance regarding the condition's non-life-threatening nature, and the dose of midodrine hydrochloride was 2.5 mg once daily. 6 Patients took midodrine hydrochloride at 6 o'clock in the morning. Group II comprised 19 patients given metoprolol as first-line therapy along with conventional therapy, and the dose of metoprolol was 0.5 mg/kg daily, twice a day. 7 Group III comprised 15 patients who only received conventional therapy. The course of treatment was 3 to 6 months.
Standing Test Protocol 1
Standing test: 1 all patients received the standing test. The test was completed in the same quiet room with the temperature of 25°C and bland light in the morning. It was preceded by 10 min of observation in the supine position, and blood pressure, heart rate and electrocardiogram were recorded before the test by using the Dash 2000 Multileads Physiological Monitor (GE company, U.S.A). The tilt angle during orthostatic stress was 90°. Then blood pressure and heart rate were monitored and electrocardiogram was recorded simultaneously during the test. However, the patients were placed in the supine from the standing position as soon as the positive response or symptoms of OI occurred. The symptoms of OI included lightheadedness, diminished concentration, tremulousness, nausea, headache, near syncope or syncope. A sustained heart rate increase >30 beats/min or a sustained rate of 120 beats/min in the first 10 min of passive upright tilt is considered diagnostic. 2
Clinical Curative Outcome
We used the criterion of scoring symptom in evaluating the symptom severity of children with POTS. 7 The standard of scoring symptom is that 0-4 score represents the severity of syncope, dizziness, chest distress, nausea, palpitation, headache and blur, respectively. A score of 0 represents no symptoms. A score of 1 represents 1 episode of 1 symptom per month. A score of 2 represents 2 to 4 episodes of 1 symptom per month. A score of 3 represents 2 to 7 episodes of 1 symptom each week. A score of 4 represents more than 1 episode of 1 symptom in 1 day.
We observed and scored the OI symptoms before therapy and 3 months to 6 months after treatment, respectively. Then, we compared the clinical data and standing test outcome of post-treatment with pre-treatment. Cure was defined by symptoms of OI disappeared. The OI symptoms decreased by 50 Midodrine and POTS in Children percent or above were regarded as improvement, and if they decreased less than 50 percent, we defined it as inefficacy. The cure rate was calculated as (the number of patients who were curative at short term follow-up)/(the total number of patients). The improvement rate was equal to (the number of patients who were improved at short term follow-up)/(the total number of the patients). The effective rate was calculated as (the number of patients who were curative plus the number of patients who were improved at short term follow-up)/(the total number of patients). Inefficacy was that the patients were neither curative nor improved at short term follow-up.
Follow-up
All patients underwent short-term follow-up after treated for 3 to 6 months and long-term follow-up for evaluating their prospective efficacy. The long term follow-up period was 15.0±4.3 months (range, 5 to 24 months). It involved eliciting information about symptom recurrence, rechecking standing test and adverse drug events. The follow-up for all patients was done by an experienced interviewer.
Statistical Analysis
Results which are found to be normally distributed are expressed as mean ± standard deviation. If the results are not normally distributed, they are reported as median and range. Continuous variables were compared using Student's t-test and analysis of variance; categorical variables were compared using Fisher's exact test. A Kaplan-Meier survivorship curve and log-rank test were used to describe the long term follow-up proportion of symptom-free cases each month. All data were analyzed using SPSS version 10.0 for Windows (SPSS Inc, Chicago, IL, USA). A P-value <0.05 was considered statistically significant.
Results
The Baseline Characteristics of Children
The baseline characteristics of children in the 3 groups were listed in Table 1 . The age, baseline symptom score, baseline systolic blood pressure, baseline diastolic blood pressure, baseline heart rate, short term follow-up and long term followup were not significantly different among group I, group II and group III (P>0.05) ( Table 1) .
The Outcome After Short-Term Follow-up
After short-term follow-up, in group I, the OI symptoms in 13 (13/19) children disappeared and in 4 (4/19) children improved after treatment. In group II, the OI symptoms in 8 (8/19) children improved after treatment, and the therapy for 6 (6/19) children was ineffective compared to pre-therapy. In group III, the OI symptoms in 5 (5/15) children improved after treatment, and the therapy for 7 (7/15) children was ineffective compared to pre-therapy ( Table 1) .
The cure rate at the end of short-term follow-up in group I was significantly higher than that of group II and group III (68.42% vs. 42.11% and 20.00%, P<0.05). The effective rate at the end of short-term follow-up in group I was also significantly higher than that of group II and group III (89.47% vs. 57.89% and 53.33%, P<0.05), but it did not differ significantly between group II and group III (P>0.05) ( Table 1) .
The systolic blood pressure difference and diastolic blood pressure difference after treatment did not differ from those before treatment in each group (P>0.05). The heart rate difference after treatment during standing test was lower than that before treatment (P<0.05) ( Table 2 ).
The Symptom Score Outcome
After treatment, the symptom score in group I was significantly lower than group II and group III, respectively (1.1±2.2 vs. 2.8±2.4 vs. 3.7±2.0, P<0.05), and significant difference was found in the symptom score between group II and group III (2.8±2.4 vs. 3.7±2.0, P<0.05) ( Table 1 ).
The Outcome of Long-Term Follow-up
During long-term follow-up, we discovered that the symptom recurrent rate in group I was significantly lower than group II and group III, respectively (P<0.05), but it did not differ significantly between group II and group III. Meanwhile, the results showed that the time of symptom improvement in group I was shorter than group II and III (Figure) . 
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Side Effects During Treatment
The blood pressure of 3 patients slightly increased during taking midodrine hydrochloride, and systolic blood pressure increased by 5 mmHg compared to that before therapy, but they did not have relevant symptoms. One child had side effect such as stomach pain during taking midodrine hydrochloride. These children could keep on taking midodrine hydrochloride and did not appear to have any side effects during taking metoprolol.
Discussion
POTS severely influenced the children's life and study. As well, it influenced the children both mentally and physically. At present, researching the therapy of POTS attracts great attention in the field. Now the treatment of POTS mainly includes increased intake of water and salt, avoidance of predisposing situations, maneuvers to prevent blood from pooling in the lower extremities (leg crossing) and to abort the episode (supine posture), and reassurance regarding the condition of non-life-threatening nature. Nowadays, fruitful achivement has been obtained in the field of autonomic nervous system disturbance. 8, 9 The research about pharmacotherapy of POTS and vasovagal syncope involves β-blockers, etc. 4,10-12 In 2000, Abe et al used β-adrenergic blockade to treat patients with postural orthostatic tachycardia syndrome and found that in 5 of these patients, symptoms were abolished and there was a smaller heart rate increase during the head-up tilt test. 13 But in 2002, Stewart et al reported that esmolol could not improve OI and hemodynamics in POTS. 4 Up to now, there are disputations on the effect of β-blockers for POTS.
In this article, we report the results of a controlled trial to investigate the efficacy of midodrine hydrochloride in the treatment of POTS of children.
Through a controlled trial, we discovered that the cure rate at the end of short-term follow-up in group I was significantly higher than that of group II and group III (68.42% vs. 42.11% and 20.00%, P<0.05). The effective rate at the end of shortterm follow-up in group I was also significantly higher than that of group II and group III (89.47% vs. 57.89% and 53.33%, P<0.05). The heart rate difference after treatment during standing test was lower than that before treatment (P<0.05). The symptom score at the end of short-term follow-up in group I was significantly lower than group II and group III, respectively (1.1±2.2 vs. 2.8±2.4 vs. 3.7±2.0, P<0.05), and there was a significant difference between group II and group III (2.8±2.4 vs. 3.7±2.0, P<0.05). We could see that after children with POTS had been treated with midodrine for 3 months to 6 months, the improvement rate of group I was higher than group II and group III, and the cure rate and effective rate of group I at short term follow-up are also higher than group II and group III, and the symptom score in group I was significantly lower than group II and group III. Meanwhile, through Kaplan-Meier survivorship curve, we discovered that the symptom recurrent rate in group I was significantly lower than group II and group III, respectively, during long term follow-up (P<0.05). The time of symptom improvement in group I was shorter than group II and III during long term follow-up.
The exact mechanisms by which midodrine hydrochloride is effective in the treatment of POTS in children are not fully understood. Midodrine hydrochloride is an oral agent which acts as a selective peripherally-acting α-adrenoceptor agonist. Since it is a selective α-agonist agent with peripheral effects, it increases peripheral vascular resistance and diminishes venous pooling. It is beneficial in treating disorders in which sympathetic release of norepinephrine is impaired at α-1 adrenergic sites. 14 However, detailed mechanisms need further studies.
Side effects during follow-up were not common. Three patients had blood pressure elevated, but they did not have autopsychic symptoms. One child had nausea and vomitting during taking midodrine hydrochloride.
However, our study still has some limitations. For example, the follow-up period in the study is not very long and the number of included patients is relatively small. The subjects with POTS strictly fullfilled the recruitment criteria and the present study is a single center one, which did limit the number of the studied cases. In spite of the limitations, we report that selective α1 adrenoceptor agonist-midodrine hydrochloride is effective in the treatment of children with POTS Figure. Kaplan-Meier survivorship curve with follow-up rate as evaluation of symptom improvement. The proportion of symptom-free cases in group I was significantly higher than group II and group III, respectively, during follow-up (P<0.05). The time of symptom improvement in group I was shorter than group II and III during follow-up. Midodrine and POTS in Children through a randomized controlled study. In the future, we will ulteriorly research its effectiveness in the treatment of POTS in children through a multi-centerred randomized doubleblinded placebo controlled study.
